$CDNA
CareDx Inc Stock $cdna

$cdna Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-K Financial Statement

#000156459018006584 Filed on March 22, 2018

Income Statement

Concept	2017 Q4	2017 Q3	2017 Q2
Revenue	$12.50M	$12.19M	$12.05M
YoY Change	15.14%	-2.28%	12.21%
Cost Of Revenue	$5.590M	$5.210M	$5.190M
YoY Change	-13.73%	100.08%	81.98%
Gross Profit	$6.910M	$6.980M	$6.860M
YoY Change	57.76%	-29.29%	-12.98%
Gross Profit Margin	55.27%	57.26%	56.95%
Selling, General & Admin	$7.300M	$7.290M	$7.400M
YoY Change	2.82%	-15.53%	-15.42%
% of Gross Profit	105.64%	104.44%	107.87%
Research & Development	$3.030M	$2.960M	$3.120M
YoY Change	-3.81%	1.02%	-0.73%
% of Gross Profit	43.85%	42.41%	45.48%
Depreciation & Amortization	$1.020M	$920.0K	$890.0K
YoY Change	41.67%	-16.36%	5.95%
% of Gross Profit	14.76%	13.18%	12.97%
Operating Expenses	$11.20M	$10.85M	$15.65M
YoY Change	9.59%	-5.24%	-11.63%
Operating Profit	-$4.290M	-$3.870M	-$3.599M
YoY Change	-26.54%	145.09%	-48.35%
Interest Expense	-$27.92M	-$10.28M	-$1.691M
YoY Change	-2837.25%	-1909.86%	-421.48%
% of Operating Profit
Other Income/Expense, Net	-$300.0K	-$320.0K	-$188.0K
YoY Change	-121.28%	146.15%	-31.39%
Pretax Income	-$32.50M	-$14.47M	-$4.411M
YoY Change	97.81%	240.63%	-59.65%
Income Tax	-$73.37M	-$180.0K	-$376.0K
% Of Pretax Income
Net Earnings	-$31.67M	-$14.27M	-$3.968M
YoY Change	104.55%	279.06%	-62.1%
Net Earnings / Revenue	-253.31%	-117.04%	-32.94%
Basic Earnings Per Share	-$1.13	-$0.63	-$0.19
Diluted Earnings Per Share	-$1.13	-$0.63	-$0.19
COMMON SHARES
Basic Shares Outstanding	27.98M	22.53M	21.41M
Diluted Shares Outstanding	27.98M	22.53M	21.41M

Balance Sheet

Concept	2017 Q4	2017 Q3	2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$16.90M	$6.000M	$9.100M
YoY Change	-2.31%	-73.09%	-46.78%
Cash & Equivalents	$16.90M	$15.53M	$18.66M
Short-Term Investments
Other Short-Term Assets	$1.400M	$1.500M	$1.500M
YoY Change	16.67%	87.5%	-16.67%
Inventory	$5.529M	$6.200M	$6.300M
Prepaid Expenses
Receivables	$2.991M	$3.300M	$3.000M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$26.77M	$16.90M	$19.90M
YoY Change	0.25%	-51.88%	-38.77%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.075M	$2.300M	$2.500M
YoY Change	-28.45%	-30.41%	-26.47%
Goodwill	$12.01M
YoY Change	-13.25%
Intangibles	$33.14M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$9.600M	$9.600M	$9.600M
YoY Change	4700.0%	31900.0%	4700.0%
Total Long-Term Assets	$56.80M	$58.19M	$57.84M
YoY Change	13.6%	-13.1%	-14.89%
TOTAL ASSETS
Total Short-Term Assets	$26.77M	$16.90M	$19.90M
Total Long-Term Assets	$56.80M	$58.19M	$57.84M
Total Assets	$83.57M	$75.09M	$77.74M
YoY Change	8.95%	-26.45%	-22.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.391M	$3.400M	$3.600M
YoY Change	9.39%	-1.85%	9.09%
Accrued Expenses	$8.700M	$8.600M	$8.700M
YoY Change	-7.45%	-29.51%	-20.18%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$15.72M	$15.00M	$33.90M
YoY Change	-31.19%	-16.21%	87.29%
Total Short-Term Liabilities	$42.91M	$31.00M	$54.20M
YoY Change	5.08%	-21.73%	41.88%
LONG-TERM LIABILITIES
Long-Term Debt	$18.34M	$21.17M	$0.00
YoY Change	1570.13%	149.22%	-100.0%
Other Long-Term Liabilities	$1.315M	$1.313M	$1.349M
YoY Change	7.61%	-87.25%	-88.66%
Total Long-Term Liabilities	$19.65M	$22.49M	$1.349M
YoY Change	747.11%	164.68%	-86.61%
TOTAL LIABILITIES
Total Short-Term Liabilities	$42.91M	$31.00M	$54.20M
Total Long-Term Liabilities	$19.65M	$22.49M	$1.349M
Total Liabilities	$89.52M	$75.27M	$65.75M
YoY Change	57.14%	56.48%	-4.15%
SHAREHOLDERS EQUITY
Retained Earnings	-$268.0M	-$236.4M	-$222.1M
YoY Change	26.1%
Common Stock	$264.2M	$238.2M	$236.6M
YoY Change	12.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$6.134M	-$311.0K	$11.83M
YoY Change
Total Liabilities & Shareholders Equity	$83.57M	$75.09M	$77.74M
YoY Change	8.91%	-26.45%	-22.65%

Cashflow Statement

Concept	2017 Q4	2017 Q3	2017 Q2
OPERATING ACTIVITIES
Net Income	-$31.67M	-$14.27M	-$3.968M
YoY Change	104.55%	279.06%	-62.1%
Depreciation, Depletion And Amortization	$1.020M	$920.0K	$890.0K
YoY Change	41.67%	-16.36%	5.95%
Cash From Operating Activities	-$2.150M	-$2.220M	-$3.200M
YoY Change	-29.74%	85.0%	-47.28%
INVESTING ACTIVITIES
Capital Expenditures	-$90.00K	-$10.00K	-$20.00K
YoY Change	-212.5%	-97.14%	-88.24%
Acquisitions
YoY Change
Other Investing Activities	-$4.950M	-$970.0K
YoY Change
Cash From Investing Activities	-$5.040M	-$980.0K	-$20.00K
YoY Change	-7300.0%	180.0%	-99.9%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	17.92M	110.0K	220.0K
YoY Change	-941.31%	-98.35%	-98.91%
NET CHANGE
Cash From Operating Activities	-2.150M	-2.220M	-3.200M
Cash From Investing Activities	-5.040M	-980.0K	-20.00K
Cash From Financing Activities	17.92M	110.0K	220.0K
Net Change In Cash	10.73M	-3.090M	-3.000M
YoY Change	-309.57%	-160.23%	-54.48%
FREE CASH FLOW
Cash From Operating Activities	-$2.150M	-$2.220M	-$3.200M
Capital Expenditures	-$90.00K	-$10.00K	-$20.00K
Free Cash Flow	-$2.060M	-$2.210M	-$3.180M
YoY Change	-34.39%	160.0%	-46.1%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	9579000
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2991000
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	143000
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2768000
CY2015	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1587000
CY2016	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-250000
CY2015	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0
CY2017	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-5863000
CY2016	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1860000
CY2015	us-gaap	License And Services Revenue LicenseAndServicesRevenue	263000
CY2015	us-gaap	Revenues Revenues	28144000
CY2015	us-gaap	Cost Of Services CostOfServices	10273000
CY2015	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-188000
CY2015	us-gaap	Cost Of Goods Sold CostOfGoodsSold	0
CY2016	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-999000
CY2015	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	823000
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	489000
CY2016	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	977000
CY2015	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	682000
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	186000
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	549000
CY2015	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0
CY2015	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	27881000
CY2015	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	0
CY2017	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-29622000
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13707000
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2015	us-gaap	Profit Loss ProfitLoss	-13707000
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-13707000
CY2015	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.16
CY2015	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.16
CY2015	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11860885
CY2015	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11860885
CY2015	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0
CY2015	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-13707000
CY2016	cdna	Stock Issued During Period Value Stock Issued Through Private Placement And Subsequent Financing StockIssuedDuringPeriodValueStockIssuedThroughPrivatePlacementAndSubsequentFinancing	2596000
CY2016	cdna	Issuance Of Common Stock Initial Public Offering IssuanceOfCommonStockInitialPublicOffering	7925000
CY2016	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	304000
CY2016	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	304000
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	19000
CY2015	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13707000
CY2014Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	41296000
CY2015	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	223000
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	46000
CY2015	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	203000
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1343000
CY2015	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	90000
CY2015Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	29494000
CY2016	cdna	Stock Issued During Period Value Business Acquisitions StockIssuedDuringPeriodValueBusinessAcquisitions	7205000
CY2016	cdna	Stock Issued During Period Value Preferred Stock Issued Through Private Placement And Subsequent Financing StockIssuedDuringPeriodValuePreferredStockIssuedThroughPrivatePlacementAndSubsequentFinancing	13064000
CY2016	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	5000
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1694000
CY2016	us-gaap	Noncontrolling Interest Increase From Business Combination NoncontrollingInterestIncreaseFromBusinessCombination	634000
CY2017	cdna	Issuance Of Common Stock Initial Public Offering IssuanceOfCommonStockInitialPublicOffering	18329000
CY2017	cdna	Stock Issued During Period Value Business Acquisitions StockIssuedDuringPeriodValueBusinessAcquisitions	1146000
CY2017	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	1676000
CY2017	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	94000
CY2017	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	245000
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	262000
CY2017	cdna	Issuance Of Common Stock For Cash Upon Exercise Of Warrants Value IssuanceOfCommonStockForCashUponExerciseOfWarrantsValue	989000
CY2017	cdna	Issuance Of Common Stock Upon Exercise Of Warrants Value IssuanceOfCommonStockUponExerciseOfWarrantsValue	4306000
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1492000
CY2017	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3759000
CY2016	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2920000
CY2015	us-gaap	Depreciation And Amortization DepreciationAndAmortization	796000
CY2017	us-gaap	Cost Of Goods Sold Depreciation CostOfGoodsSoldDepreciation	418000
CY2016	us-gaap	Cost Of Goods Sold Depreciation CostOfGoodsSoldDepreciation	4175000
CY2015	us-gaap	Cost Of Goods Sold Depreciation CostOfGoodsSoldDepreciation	0
CY2017	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-10000
CY2016	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
CY2015	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	2000
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	1744000
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	1998000
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	1341000
CY2017	cdna	Amortization Of Deferred Revenue AmortizationOfDeferredRevenue	32000
CY2016	cdna	Amortization Of Deferred Revenue AmortizationOfDeferredRevenue	45000
CY2015	cdna	Amortization Of Deferred Revenue AmortizationOfDeferredRevenue	130000
CY2017	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3452000
CY2016	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	-101000
CY2015	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	247000
CY2017	cdna	Loss On Conversion Of Debt To Equity LossOnConversionOfDebtToEquity	274000
CY2016	cdna	Loss On Conversion Of Debt To Equity LossOnConversionOfDebtToEquity	0
CY2015	cdna	Loss On Conversion Of Debt To Equity LossOnConversionOfDebtToEquity	0
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	109000
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1047000
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-320000
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1025000
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-492000
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	80000
CY2017	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	84000
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	292000
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-620000
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1199000
CY2017	cdna	Proceeds From Issuance Of Common Stock Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts	18328000
CY2016	cdna	Proceeds From Issuance Of Common Stock Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts	7926000
CY2015	cdna	Proceeds From Issuance Of Common Stock Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts	0
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-14307000
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-16523000
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-9752000
CY2017	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	24002000
CY2017	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	1065000
CY2017	us-gaap	Increase Decrease In Royalties Payable IncreaseDecreaseInRoyaltiesPayable	-263000
CY2016	us-gaap	Increase Decrease In Royalties Payable IncreaseDecreaseInRoyaltiesPayable	21000
CY2015	us-gaap	Increase Decrease In Royalties Payable IncreaseDecreaseInRoyaltiesPayable	1000
CY2017	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-970000
CY2016	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-105000
CY2015	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	1240000
CY2017	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	2088000
CY2016	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	1340000
CY2015	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	0
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1199000
CY2017	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	59000
CY2016	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0
CY2015	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-6164000
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-21117000
CY2016	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	0
CY2015	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	15625000
CY2017	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	14359000
CY2016	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	3944000
CY2015	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	11466000
CY2017	us-gaap	Proceeds From Repayments Of Restricted Cash Financing Activities ProceedsFromRepaymentsOfRestrictedCashFinancingActivities	-9375000
CY2016	us-gaap	Proceeds From Repayments Of Restricted Cash Financing Activities ProceedsFromRepaymentsOfRestrictedCashFinancingActivities	0
CY2015	us-gaap	Proceeds From Repayments Of Restricted Cash Financing Activities ProceedsFromRepaymentsOfRestrictedCashFinancingActivities	0
CY2017	cdna	Proceeds From Private Placement And Subsequent Financing Net Of Issuance Costs ProceedsFromPrivatePlacementAndSubsequentFinancingNetOfIssuanceCosts	0
CY2016	cdna	Proceeds From Private Placement And Subsequent Financing Net Of Issuance Costs ProceedsFromPrivatePlacementAndSubsequentFinancingNetOfIssuanceCosts	20622000
CY2015	cdna	Proceeds From Private Placement And Subsequent Financing Net Of Issuance Costs ProceedsFromPrivatePlacementAndSubsequentFinancingNetOfIssuanceCosts	0
CY2017	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	989000
CY2016	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0
CY2015	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	262000
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	19000
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	46000
CY2017	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	94000
CY2016	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	304000
CY2015	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	203000
CY2017	us-gaap	Proceeds From Repayments Of Bank Overdrafts ProceedsFromRepaymentsOfBankOverdrafts	63000
CY2016	us-gaap	Proceeds From Repayments Of Bank Overdrafts ProceedsFromRepaymentsOfBankOverdrafts	0
CY2015	us-gaap	Proceeds From Repayments Of Bank Overdrafts ProceedsFromRepaymentsOfBankOverdrafts	0
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	20004000
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	24927000
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	4408000
CY2017	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	104000
CY2016	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	83000
CY2015	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	0
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-363000
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-12630000
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-6543000
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29888000
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36431000
CY2017	us-gaap	Interest Paid Net InterestPaidNet	3270000
CY2016	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	0
CY2015	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	25000
CY2017	cdna	Common Stock Issued For Acquisition CommonStockIssuedForAcquisition	0
CY2016	cdna	Common Stock Issued For Acquisition CommonStockIssuedForAcquisition	7205000
CY2015	cdna	Common Stock Issued For Acquisition CommonStockIssuedForAcquisition	0
CY2017	cdna	Debt Assumed As Part Of Acquisition DebtAssumedAsPartOfAcquisition	0
CY2016	cdna	Shares Issued In Lieu Of Cash Payment SharesIssuedInLieuOfCashPayment	0
CY2015	cdna	Shares Issued In Lieu Of Cash Payment SharesIssuedInLieuOfCashPayment	0
CY2017	cdna	Business Acquisition Deferred Payment Consideration BusinessAcquisitionDeferredPaymentConsideration	0
CY2016	cdna	Business Acquisition Deferred Payment Consideration BusinessAcquisitionDeferredPaymentConsideration	5700000
CY2015	cdna	Business Acquisition Deferred Payment Consideration BusinessAcquisitionDeferredPaymentConsideration	0
CY2017	cdna	Accrued Interest Capitalized To Debt Principal AccruedInterestCapitalizedToDebtPrincipal	984000
CY2016	cdna	Accrued Interest Capitalized To Debt Principal AccruedInterestCapitalizedToDebtPrincipal	0
CY2015	cdna	Accrued Interest Capitalized To Debt Principal AccruedInterestCapitalizedToDebtPrincipal	0
CY2017	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	0
CY2016	us-gaap	Interest Paid Net InterestPaidNet	867000
CY2015	us-gaap	Interest Paid Net InterestPaidNet	1364000
CY2017	cdna	Shares Issued In Lieu Of Cash Payment SharesIssuedInLieuOfCashPayment	1145000
CY2016	cdna	Debt Assumed As Part Of Acquisition DebtAssumedAsPartOfAcquisition	13421000
CY2015	cdna	Debt Assumed As Part Of Acquisition DebtAssumedAsPartOfAcquisition	0
CY2017	cdna	Conversion Of Convertible Preferred Stock To Common Stock At Private Placement And Subsequent Financing ConversionOfConvertiblePreferredStockToCommonStockAtPrivatePlacementAndSubsequentFinancing	0
CY2016	cdna	Conversion Of Convertible Preferred Stock To Common Stock At Private Placement And Subsequent Financing ConversionOfConvertiblePreferredStockToCommonStockAtPrivatePlacementAndSubsequentFinancing	13064000
CY2015	cdna	Conversion Of Convertible Preferred Stock To Common Stock At Private Placement And Subsequent Financing ConversionOfConvertiblePreferredStockToCommonStockAtPrivatePlacementAndSubsequentFinancing	0
CY2017	cdna	Debt Conversion Converted Instrument Common Stock Warrants Issued DebtConversionConvertedInstrumentCommonStockWarrantsIssued	0
CY2016	cdna	Debt Conversion Converted Instrument Common Stock Warrants Issued DebtConversionConvertedInstrumentCommonStockWarrantsIssued	0
CY2015	cdna	Debt Conversion Converted Instrument Common Stock Warrants Issued DebtConversionConvertedInstrumentCommonStockWarrantsIssued	90000
CY2017	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Use of Estimates </font></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in the consolidated financial statements and accompanying notes.  On an ongoing basis, management evaluates its estimates, including those related to (i) revenue recognition; (ii) the differences between amounts billed and estimated receipts from payers; (iii) the determination of the accruals for clinical studies; (iv) the determination of refunds to be requested by third-party payers; (v) the fair value of assets and liabilities, including from acquisitions; (vi) inventory valuation; (vii) the valuation of warrants, Series A Preferred, and common stock issued in the Private Placement and Subsequent Financing (as described in Note 11); (viii) the fair value of contingent consideration in a business acquisition; (ix) the fair value of embedded derivatives; (x) measurement of stock-based compensation expense; (xi) the determination of the valuation allowance and estimated tax benefit associated with deferred tax assets and net deferred tax liability; (xii) any impairment of long-lived assets, including in-process technology and goodwill; and (xiii) legal contingencies. Actual results could differ from those estimates. </p></div>
CY2017	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Concentrations of Credit Risk and Other Risks and Uncertainties </font></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and accounts receivable.  The Company’s policy is to invest its cash and cash equivalents in money market funds, obligations of U.S. government agencies and government-sponsored entities, commercial paper and various bank deposit accounts.  These financial instruments were held in Company accounts at eight financial institutions.  The counterparties to the agreements relating to the Company’s investments consist of financial institutions of high credit standing.  The Company is exposed to credit risk in the event of default by the financial institutions to the extent of amounts recorded on the balance sheets that may be in excess of insured limits. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is also subject to credit risk from its accounts receivable, which are derived from revenue earned from AlloMap and AlloSure tests provided for patients located in the U.S. and billed to various third-party payers, and from sales of pre-transplant products to distributors, strategic partners and end customers in Europe, the Middle East, and Africa, the U.S., Latin America and other geographic regions.  The Company has not experienced any significant credit losses and does not generally require collateral on receivables.  For the years ended December 31, 2017, 2016 and 2015, approximately 27%, 44% and 50%, respectively, of testing revenue was billed to Medicare.  No other payers represented more than 10% of testing revenue for these periods and no payers represented more than 10% of product revenue for the years ended December 31, 2017 and 2016. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2017 and 2016, approximately 16% and 27%, respectively, of accounts receivable was due from Medicare.  No other payer represented more than 10% of accounts receivable at either December 31, 2017 or 2016. </p></div>
CY2017	us-gaap	Revenue Recognition Sales Of Goods RevenueRecognitionSalesOfGoods	<div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Product Revenue</font></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product revenue is recognized from the sale of products to end-users, distributors and strategic partners when (i) persuasive evidence of an arrangement exists, (ii) the product is complete and tested and has been shipped or delivered, as required to transfer title and risk of loss, (iii) the sales price is fixed and determinable, (iv) collection of the resulting receivable is reasonably assured, (v) there are no material contingencies and (vi) the Company does not have significant obligations for future performance.  When collectability of the receivable is not reasonably assured, the Company defers the revenue until the cash is received.  Provisions for estimated future product returns and allowances are recorded in the period of the sale based on the historical and anticipated future rate of returns.  Revenue is recorded net of any discounts given to the buyer. </p></div>
CY2017	us-gaap	Revenue Recognition Multiple Element Arrangements RevenueRecognitionMultipleElementArrangements	<div> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Collaboration and License Revenue </font></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company generates revenue from collaboration and license agreements.  Collaboration and license agreements may include non-refundable upfront payments, partial or complete reimbursement of research and development costs, contingent payments based on the occurrence of specified events under the agreements, license fees and royalties on sales of products or product candidates if they are successfully commercialized.  The Company’s performance obligations under the collaborations may include the transfer of intellectual property rights in the form of licenses, obligations to provide research and development services and obligations to participate on certain development committees with the collaboration partners.  The Company makes judgments that affect the periods over which it recognizes revenue.  The Company periodically reviews its estimated periods of performance based on the progress under each arrangement and accounts for the impact of any change in estimated periods of performance on a prospective basis. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes contingent consideration received from the achievement of a substantive milestone in its entirety in the period in which the milestone is achieved.  The Company believes this approach is consistent with the substance of its performance under its various license and collaboration agreements.  The Company did not recognize any revenue connected with milestones during the years ended December 31, 2017, 2016 or 2015. </p></div>
CY2017	us-gaap	Advertising Cost Policy Expensed Advertising Cost AdvertisingCostPolicyExpensedAdvertisingCost	<div> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Advertising Expenses</font></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All advertising costs are expensed as incurred.  Advertising expenses were insignificant during all the periods presented.</p></div>
CY2017	cdna	Schedule Of Maturities Of Debt Table Tex Block ScheduleOfMaturitiesOfDebtTableTexBlock	<div> <p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2017, future debt maturities were as follows (in thousands):</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.78%; border-bottom:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ending December 31,</p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.96%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.78%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,353</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,420</p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,905</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total debt maturities</p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,678</p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: debt discount and issuance costs</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,619</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total debt maturities, net of debt discount and issuance costs</p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,059</p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: current portion, of long-term debt</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,721</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.78%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term debt, net of current portion</p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,338</p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p></div>
CY2017	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2
CY2017Q4	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	34100000
CY2017	us-gaap	Additional Cash And Cash Equivalent Related Text AdditionalCashAndCashEquivalentRelatedText	Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less from the date of purchase.
CY2017	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2017	us-gaap	Revenue Recognition Milestone Method Revenue Recognized RevenueRecognitionMilestoneMethodRevenueRecognized	0
CY2016	us-gaap	Revenue Recognition Milestone Method Revenue Recognized RevenueRecognitionMilestoneMethodRevenueRecognized	0
CY2015	us-gaap	Revenue Recognition Milestone Method Revenue Recognized RevenueRecognitionMilestoneMethodRevenueRecognized	0
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-55469000
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-39469000
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-13707000
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12411471
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5551325
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2212431
CY2016Q2	cdna	Preferred Stock Issued Shares Private Placement PreferredStockIssuedSharesPrivatePlacement	4630145
CY2016Q2	cdna	Preferred Stock Issued Shares Subsequent Financing PreferredStockIssuedSharesSubsequentFinancing	4630145
CY2017	cdna	Fair Value Measurements Inter Transfers Between Levels FairValueMeasurementsInterTransfersBetweenLevels	0
CY2016	cdna	Fair Value Measurements Inter Transfers Between Levels FairValueMeasurementsInterTransfersBetweenLevels	0
CY2017	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	85000
CY2017	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	39000
CY2017	us-gaap	Number Of Reporting Units NumberOfReportingUnits	2
CY2017	us-gaap	New Date Of Annual Goodwill Impairment Test NewDateOfAnnualGoodwillImpairmentTest	On January 1, 2017, the Company adopted ASU 2017-04, which eliminated the Step 2 requirement of the goodwill impairment test. Instead, the goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. The new standard simplifies how an entity is required to test goodwill for impairment and reduces the cost and complexity of evaluating goodwill for impairment. The Company determined that the decrease in its market capitalization constituted an indicator of impairment and therefore a goodwill impairment test was completed as of March 31, 2017.
CY2017	us-gaap	Goodwill Impaired Method For Fair Value Determination GoodwillImpairedMethodForFairValueDetermination	determined that the fair value of the reporting units exceeded the respective carrying values.
CY2017Q4	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2017Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	37875000
CY2017Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	4166000
CY2017Q4	cdna	Finite Lived Intangible Foreign Currency Translation FiniteLivedIntangibleForeignCurrencyTranslation	570000
CY2017Q4	cdna	Accrued Clinical And Cost Of Other Studies Current AccruedClinicalAndCostOfOtherStudiesCurrent	1115000
CY2016Q4	cdna	Accrued Clinical And Cost Of Other Studies Current AccruedClinicalAndCostOfOtherStudiesCurrent	1375000
CY2017Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	13000
CY2016Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	68000
CY2017Q4	cdna	Accrued Debt Financing Fees Current AccruedDebtFinancingFeesCurrent	0
CY2016Q4	cdna	Accrued Debt Financing Fees Current AccruedDebtFinancingFeesCurrent	600000
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15484000
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14155000
CY2017	us-gaap	Adjustment For Amortization AdjustmentForAmortization	135000
CY2016	us-gaap	Adjustment For Amortization AdjustmentForAmortization	204000
CY2015	us-gaap	Adjustment For Amortization AdjustmentForAmortization	79000
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	382000
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	440000
CY2017	cdna	Leases Expiration Period LeasesExpirationPeriod	2020
CY2017Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	33139000
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2600000
CY2016	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1700000
CY2015	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0
CY2017Q4	cdna	Indefinite Lived Intangible Assets Excluding Goodwill Gross IndefiniteLivedIntangibleAssetsExcludingGoodwillGross	6700000
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	3017000
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	3017000
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	3017000
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	3017000
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	3017000
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	18054000
CY2017Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2569000
CY2016Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4199000
CY2017Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1471000
CY2016Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	159000
CY2017Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1489000
CY2016Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1103000
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	17559000
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	17086000
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	475000
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	620000
CY2017Q4	cdna	Accrued Sample Processing Fees AccruedSampleProcessingFees	633000
CY2016Q4	cdna	Accrued Sample Processing Fees AccruedSampleProcessingFees	524000
CY2017Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	419000
CY2016Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	374000
CY2017Q4	cdna	Accrued Uninvoiced Receipts AccruedUninvoicedReceipts	253000
CY2016Q4	cdna	Accrued Uninvoiced Receipts AccruedUninvoicedReceipts	0
CY2017Q4	cdna	Accrued Over Payments And Refunds AccruedOverPaymentsAndRefunds	270000
CY2016Q4	cdna	Accrued Over Payments And Refunds AccruedOverPaymentsAndRefunds	281000
CY2017Q4	cdna	Accrued Software Implementation Costs AccruedSoftwareImplementationCosts	94000
CY2016Q4	cdna	Accrued Software Implementation Costs AccruedSoftwareImplementationCosts	176000
CY2017Q4	us-gaap	Interest Payable Current InterestPayableCurrent	81000
CY2016Q4	us-gaap	Interest Payable Current InterestPayableCurrent	862000
CY2017	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1700000
CY2016	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1500000
CY2015	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1000000
CY2017Q4	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	25000
CY2017Q4	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	5000
CY2017Q4	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	0
CY2017Q4	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	0
CY2017Q4	us-gaap	Capital Leases Future Minimum Payments Due Thereafter CapitalLeasesFutureMinimumPaymentsDueThereafter	0
CY2017Q4	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	30000
CY2017Q4	us-gaap	Capital Leases Future Minimum Payments Interest Included In Payments CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments	3000
CY2017Q4	us-gaap	Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments	27000
CY2017Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	14000
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	2209000
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	2149000
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	2104000
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	10000
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	8000
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	6480000
CY2017	cdna	License And Maintenance Fees LicenseAndMaintenanceFees	100000
CY2016Q3	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	1300000
CY2017	cdna	Description Of Agreement Expected Expiration Year DescriptionOfAgreementExpectedExpirationYear	The agreement will expire at the later of the last-to-expire patent in the EEA or ten years from the first commercial sale of the test in the EEA, which occurred in 2014.
CY2013Q2	cdna	Potential Refundable Portion Of Upfront Payment PotentialRefundablePortionOfUpfrontPayment	250000
CY2013Q2	cdna	Potential Refundable Portion Of Upfront Payment PotentialRefundablePortionOfUpfrontPayment	263000
CY2013Q2	cdna	Upfront Payment In Cash UpfrontPaymentInCash	387500
CY2013Q2	cdna	Upfront Payment In Cash UpfrontPaymentInCash	408000
CY2017	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue	39000
CY2016	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue	2000
CY2015	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue	46000
CY2017	us-gaap	Royalty Revenue RoyaltyRevenue	500000
CY2016	us-gaap	Royalty Revenue RoyaltyRevenue	200000
CY2015	us-gaap	Royalty Revenue RoyaltyRevenue	200000
CY2017Q4	cdna	Royalty Revenue Receivable RoyaltyRevenueReceivable	0
CY2016Q4	cdna	Royalty Revenue Receivable RoyaltyRevenueReceivable	0
CY2017Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	300000
CY2016Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	900000
CY2017Q4	cdna	Long Term Debt Maturities Repayments In Next Twelve Months LongTermDebtMaturitiesRepaymentsInNextTwelveMonths	17353000
CY2017Q4	cdna	Long Term Debt Maturities Repayments In Year Two LongTermDebtMaturitiesRepaymentsInYearTwo	15420000
CY2017Q4	cdna	Long Term Debt Maturities Repayments In Year Three LongTermDebtMaturitiesRepaymentsInYearThree	5905000
CY2017Q4	cdna	Long Term Debt Maturities Repayments LongTermDebtMaturitiesRepayments	38678000
CY2017Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	4619000
CY2017Q4	us-gaap	Long Term Debt LongTermDebt	34059000
CY2015Q1	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	20000000
CY2017Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	11200000
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	200000
CY2017	cdna	Prepayment Penalty PrepaymentPenalty	0.00
CY2016Q2	cdna	Common Stock Purchase Price CommonStockPurchasePrice	3.99
CY2016Q2	us-gaap	Fees And Commissions Transfer Agent FeesAndCommissionsTransferAgent	1800000
CY2017	cdna	Additional Issued Units AdditionalIssuedUnits	334169
CY2016Q2	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	1700000
CY2016Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1002507
CY2017	cdna	Estimated Fair Value Of Warrant Liability Remeasurement Charge EstimatedFairValueOfWarrantLiabilityRemeasurementCharge	11300000
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	718007
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	357075
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	652078
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	8200
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	77660
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	5329
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	361672
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	512575
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	597470
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	61305
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	0
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	269212
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.91
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.29
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	6.64
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	8.88
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.15
CY2017	cdna	Share Based Compensation Arrangement By Share Based Payment Award Weighted Average Exercised Price Shares Reserved ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageExercisedPriceSharesReserved	0
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.39
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.64
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	9
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	5.81
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	107601
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	365074
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	357075
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	909913
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	80891
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	0
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	522826
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	165924
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	156429
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1031804
CY2015	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Assumed From Acquisitions In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedFromAcquisitionsInPeriod	0
CY2015	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	23576
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1577317
CY2016	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Assumed From Acquisitions In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedFromAcquisitionsInPeriod	0
CY2016	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	5688
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1792286
CY2017	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Assumed From Acquisitions In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedFromAcquisitionsInPeriod	0
CY2017	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	71976
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1941473
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.36
CY2015	cdna	Share Based Compensation Arrangement By Share Based Payment Award Weighted Average Exercised Price Shares Reserved ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageExercisedPriceSharesReserved	0
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.09
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.94
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	8.13
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	10.36
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.87
CY2016	cdna	Share Based Compensation Arrangement By Share Based Payment Award Weighted Average Exercised Price Shares Reserved ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageExercisedPriceSharesReserved	0
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.21
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	200000
CY2017Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	1941472
CY2017Q4	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber	942530
CY2017Q4	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber	998942
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1941472
CY2017	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice	4.46
CY2017Q4	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice	3.96
CY2017	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm	P6Y6M10D
CY2017	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm	P8Y9M
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
CY2017Q4	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue	2591000
CY2017Q4	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue	876000
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	3467000
CY2017Q4	us-gaap	Share Price SharePrice	7.34
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.60
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.05
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.53
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	700000
CY2017Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1400000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-50132000
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-21753000
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-13707000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-7137000
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-19609000
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	0
CY2017	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y8M12D
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1744000
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1998000
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1341000
CY2017	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0
CY2017	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	0
CY2017	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	74000
CY2016	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	49000
CY2015	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2017	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-4000
CY2016	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	11000
CY2015	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0
CY2017	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	68000
CY2016	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	32000
CY2015	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0
CY2017	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	138000
CY2016	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	92000
CY2015	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0
CY2017	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	42000
CY2016	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-251000
CY2015	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2017	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	1000
CY2016	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-49000
CY2015	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2017	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1890000
CY2016	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1398000
CY2015	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1847000
CY2016	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1698000
CY2015	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.002
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.005
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.019
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.380
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.168
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.311
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.011
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.013
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.000
CY2017	cdna	Effective Income Tax Rate Reconciliation Warrant Revaluation EffectiveIncomeTaxRateReconciliationWarrantRevaluation	-0.175
CY2016	cdna	Effective Income Tax Rate Reconciliation Warrant Revaluation EffectiveIncomeTaxRateReconciliationWarrantRevaluation	-0.002
CY2015	cdna	Effective Income Tax Rate Reconciliation Warrant Revaluation EffectiveIncomeTaxRateReconciliationWarrantRevaluation	0.000
CY2017	cdna	Effective Income Tax Rate Reconciliation Interest Expense EffectiveIncomeTaxRateReconciliationInterestExpense	-0.018
CY2016	cdna	Effective Income Tax Rate Reconciliation Interest Expense EffectiveIncomeTaxRateReconciliationInterestExpense	0.000
CY2015	cdna	Effective Income Tax Rate Reconciliation Interest Expense EffectiveIncomeTaxRateReconciliationInterestExpense	0.000
CY2017	cdna	Effective Income Tax Rate Reconciliation Acquisition Costs EffectiveIncomeTaxRateReconciliationAcquisitionCosts	0.000
CY2016	cdna	Effective Income Tax Rate Reconciliation Acquisition Costs EffectiveIncomeTaxRateReconciliationAcquisitionCosts	-0.012
CY2015	cdna	Effective Income Tax Rate Reconciliation Acquisition Costs EffectiveIncomeTaxRateReconciliationAcquisitionCosts	-0.032
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	-0.012
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	79429000
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	76295000
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	-0.108
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	0.000
CY2017	cdna	Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit Percent TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefitPercent	-0.465
CY2016	cdna	Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit Percent TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefitPercent	0.00
CY2015	cdna	Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit Percent TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefitPercent	0.00
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.007
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.007
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.022
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.030
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.039
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	49374000
CY2017Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	5798000
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	583000
CY2017Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1184000
CY2017Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	633000
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	57572000
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	54934000
CY2017Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	2638000
CY2017Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	7554000
CY2017Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	17000
CY2017Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	7571000
CY2017Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	4933000
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	71925000
CY2016Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	4947000
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	1274000
CY2016Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	195000
CY2016Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1088000
CY2016Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	3134000
CY2016Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	8979000
CY2016Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	212000
CY2016Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	9191000
CY2016Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	6057000
CY2017	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-21400000
CY2016	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	6200000
CY2016	cdna	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Deferred Tax Assets TaxCutsAndJobsActOf2017IncompleteAccountingDeferredTaxAssets	72500000
CY2017	cdna	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Deferred Tax Assets TaxCutsAndJobsActOf2017IncompleteAccountingDeferredTaxAssets	45900000
CY2017Q4	cdna	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Decreasing Valuation Allowance TaxCutsAndJobsActOf2017IncompleteAccountingDecreasingValuationAllowance	27000000
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5252000
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2431000
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2054000
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	186000
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	332000
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	372000
CY2017	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	2274000
CY2016	cdna	Unrecognized Tax Benefits Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsResultingFromPriorPeriodTaxPositions	2489000
CY2015	cdna	Unrecognized Tax Benefits Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsResultingFromPriorPeriodTaxPositions	5000
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3164000
CY2017Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	500000
CY2017Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	300000
CY2016Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	300000
CY2015Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2017	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0
CY2017	cdna	Intersegment Sales IntersegmentSales	0
CY2017Q1	us-gaap	Revenues Revenues	11584000
CY2017Q2	us-gaap	Revenues Revenues	12046000
CY2017Q3	us-gaap	Revenues Revenues	12191000
CY2017Q4	us-gaap	Revenues Revenues	12503000
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-5562000
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-3968000
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-14268000
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	-31671000
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
CY2017Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2017Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.63
CY2017Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.13
CY2017Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
CY2017Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
CY2017Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.63
CY2017Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.13
CY2017Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21343782
CY2017Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21412480
CY2017Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22526615
CY2017Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27983033
CY2017Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21343782
CY2017Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21412480
CY2017Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22526615
CY2017Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27983033
CY2017Q1	us-gaap	Assets Assets	80322000
CY2017Q2	us-gaap	Assets Assets	77738000
CY2017Q3	us-gaap	Assets Assets	75093000
CY2017Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0
CY2017Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0
CY2017Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	21174000
CY2016Q1	us-gaap	Revenues Revenues	6562000
CY2016Q2	us-gaap	Revenues Revenues	10735000
CY2016Q3	us-gaap	Revenues Revenues	12475000
CY2016Q4	us-gaap	Revenues Revenues	10859000
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-9752000
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-10470000
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-3764000
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	-15483000
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.81
CY2016Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.77
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
CY2016Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.73
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.81
CY2016Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.77
CY2016Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
CY2016Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.73
CY2016Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11969714
CY2016Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13568120
CY2016Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19098626
CY2016Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21270151
CY2016Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11969714
CY2016Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13568120
CY2016Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19481424
CY2016Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21270151
CY2016Q1	us-gaap	Assets Assets	48834000
CY2016Q2	us-gaap	Assets Assets	100453000
CY2016Q3	us-gaap	Assets Assets	102092000
CY2016Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	11368000
CY2016Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	10072000
CY2016Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	8496000

Files In Submission

Name	View Source	Status
0001564590-18-006584-index-headers.html	Edgar Link	pending
0001564590-18-006584-index.html	Edgar Link	pending
0001564590-18-006584.txt	Edgar Link	pending
0001564590-18-006584-xbrl.zip	Edgar Link	pending
cdna-10k_20171231.htm	Edgar Link	pending
cdna-20171231.xml	Edgar Link	completed
cdna-20171231.xsd	Edgar Link	pending
cdna-20171231_cal.xml	Edgar Link	unprocessable
cdna-20171231_def.xml	Edgar Link	unprocessable
cdna-20171231_lab.xml	Edgar Link	unprocessable
cdna-20171231_pre.xml	Edgar Link	unprocessable
cdna-ex106_701.htm	Edgar Link	pending
cdna-ex211_11.htm	Edgar Link	pending
cdna-ex231_10.htm	Edgar Link	pending
cdna-ex311_7.htm	Edgar Link	pending
cdna-ex312_9.htm	Edgar Link	pending
cdna-ex321_6.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CDNA
CareDx Inc Stock $cdna

2017 Q4 Form 10-K Financial Statement

#000156459018006584 Filed on March 22, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDNA CareDx Inc Stock $cdna

2017 Q4 Form 10-K Financial Statement

#000156459018006584 Filed on March 22, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDNA
CareDx Inc Stock $cdna